

Renuka Iyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8925548/publications.pdf>

Version: 2024-02-01

37
papers

1,436
citations

471371

17
h-index

345118

36
g-index

38
all docs

38
docs citations

38
times ranked

2564
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 4317-4345.	0.8	350
2	NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 563-573.	2.3	272
3	Sorafenib: a clinical and pharmacologic review. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1943-1955.	0.9	131
4	PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. <i>JCI Insight</i> , 2016, 1, .	2.3	60
5	Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. <i>Cancers</i> , 2018, 10, 510.	1.7	53
6	Augmentation of IFN- γ + CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. <i>JCI Insight</i> , 2019, 4, .	2.3	52
7	Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, E30-3.	0.6	51
8	Quality of life and hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 296-317.	0.6	43
9	Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. <i>Current Oncology Reports</i> , 2016, 18, 7.	1.8	38
10	Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study. <i>PLoS ONE</i> , 2018, 13, e0198809.	1.1	37
11	A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 311-320.	0.9	35
12	Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. <i>Cancers</i> , 2019, 11, 1980.	1.7	29
13	Erlotinib and Radiation Therapy for Elderly Patients with Esophageal Cancer - Clinical and Correlative Results from a Prospective Multicenter Phase 2 Trial. <i>Oncology</i> , 2013, 85, 53-58.	0.9	25
14	Immunomodulation in hepatocellular cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 208-219.	0.6	22
15	Combined Hepatocholangiocarcinoma: Case-Series and Review of Literature. <i>International Journal of Gastrointestinal Cancer</i> , 2006, 37, 27-34.	0.4	21
16	Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. <i>Cancers</i> , 2019, 11, 873.	1.7	19
17	Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 441-448.	0.6	17
18	Role of Adjuvant Chemotherapy in Pulmonary Carcinoids: An NCDB Analysis. <i>Anticancer Research</i> , 2019, 39, 6835-6842.	0.5	16

#	ARTICLE	IF	CITATIONS
19	Mutant <i>PPM1D</i> - and <i>TP53</i> -Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. <i>JCO Precision Oncology</i> , 2022, 6, e2100309.	1.5	15
20	Molecular Targets in Biliary Carcinogenesis and Implications for Therapy. <i>Oncologist</i> , 2015, 20, 742-751.	1.9	14
21	Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis. <i>Liver Cancer</i> , 2020, 9, 549-562.	4.2	14
22	A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 497-505.	1.1	13
23	Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2020, 25, e1825-e1836.	1.9	13
24	Exploring the role of survivin in neuroendocrine neoplasms. <i>Oncotarget</i> , 2020, 11, 2246-2258.	0.8	11
25	Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 253-8.	0.6	11
26	Endothelial progenitor cell number and ERK phosphorylation serve as predictive and prognostic biomarkers in advanced hepatocellular carcinoma patients treated with sorafenib. <i>Oncolmmunology</i> , 2016, 5, e1226718.	2.1	10
27	Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 433-9.	0.6	10
28	A phase I study of the <i>anaplastic lymphoma kinase</i> inhibitor ceritinib in combination with <i>gemcitabine</i> -based chemotherapy in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2021, 149, 2063-2074.	2.3	8
29	Targeted therapy in gastrointestinal malignancies. <i>Journal of Carcinogenesis</i> , 2014, 13, 4.	2.5	7
30	Gemcitabine and capecitabine for advanced biliary cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 728-736.	0.6	6
31	Interleukin-6 as a biomarker in patients with hepatobiliary cancers. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 537-545.	0.6	6
32	Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test. <i>Cancers</i> , 2021, 13, 3109.	1.7	6
33	Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review. <i>Cancers</i> , 2022, 14, 1428.	1.7	6
34	A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. <i>Cancer</i> , 2018, 124, 3890-3899.	2.0	5
35	Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies. <i>Archives of Biochemistry and Biophysics</i> , 2019, 661, 97-106.	1.4	5
36	Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. <i>Communications Biology</i> , 2021, 4, 862.	2.0	5

#	ARTICLE	IF	CITATIONS
37	Immunotherapy in hepatocellular cancer. <i>Advances in Cancer Research</i> , 2021, 149, 295-320.	1.9	0